For: | Tovo CV, de Mattos AZ, Coral GP, Sartori GDP, Nogueira LV, Both GT, Villela-Nogueira CA, de Mattos AA. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol 2023; 29(2): 343-356 [PMID: 36687125 DOI: 10.3748/wjg.v29.i2.343] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v29/i2/343.htm |
Number | Citing Articles |
1 |
Sharmila Fagoonee, Ralf Weiskirchen. MicroRNAs and RNA-Binding Protein-Based Regulation of Bone Metastasis from Hepatobiliary Cancers and Potential Therapeutic Strategies. Cells 2024; 13(23): 1935 doi: 10.3390/cells13231935
|
2 |
Zahid Ijaz Tarar, Umer Farooq, Faisal Inayat, Sanket D Basida, Faisal Ibrahim, Mustafa Gandhi, Gul Nawaz, Arslan Afzal, Ammad J Chaudhary, Faisal Kamal, Ahmad H Ali, Yezaz A Ghouri. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis. World Journal of Experimental Medicine 2024; 14(4): 98543 doi: 10.5493/wjem.v14.i4.98543
Abstract(168) |
Core Tip(69) |
Full Article(HTML)(1537)
|
Full Article with Cover (PDF)-3047K(12)
|
Audio-4191K(0)
|
Peer-Review Report-222K(4)
|
Answering Reviewers-64K(4)
|
Supplementary Material-146K(5)
|
Full Article (PDF)-2750K(148)
|
Full Article (XML)-172K(6)
|
Times Cited (0)
|
Total Visits (2373)
|
Open
|
3 |
Madalina-Gabriela Taru, Monica Lupsor-Platon. Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography. Cancers 2023; 15(16): 4097 doi: 10.3390/cancers15164097
|
4 |
Peijun Xu, Maoyun Liu, Miao Liu, Ai Shen. Management of non-alcoholic fatty liver disease-associated hepatocellular carcinoma. BioScience Trends 2024; 18(5): 431 doi: 10.5582/bst.2024.01295
|
5 |
Cornelius J Fernandez, Lakshmi Nagendra, Joseph M Pappachan. Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action. touchREVIEWS in Endocrinology 2023; 20(1): 1 doi: 10.17925/EE.2023.20.1.1
|
6 |
Noah J. Daniels, Courtney E. Hershberger, Matthew Kerosky, Chase J. Wehrle, Roma Raj, Nihal Aykun, Daniela S. Allende, Federico N. Aucejo, Daniel M. Rotroff. Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva. International Journal of Molecular Sciences 2024; 25(18): 10144 doi: 10.3390/ijms251810144
|
7 |
Junyu Wu, Hor-Yue Tan, Yau-Tuen Chan, Yuanjun Lu, Zixin Feng, Hongchao Yuan, Cheng Zhang, Yibin Feng, Ning Wang. PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer. Journal of Experimental & Clinical Cancer Research 2024; 43(1) doi: 10.1186/s13046-024-02967-3
|
8 |
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, Marcelo Dib Bechara, Lucas Fornari Laurindo, Nahum Méndez-Sánchez, Sandra Maria Barbalho. Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. International Journal of Molecular Sciences 2024; 25(7): 3694 doi: 10.3390/ijms25073694
|
9 |
Centura R. Anbarasu, Sophia Williams-Perez, Ernest R. Camp, Derek J. Erstad. Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers 2024; 16(16): 2773 doi: 10.3390/cancers16162773
|
10 |
Abraham Koshy. Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024. Journal of Clinical and Experimental Hepatology 2025; 15(1): 102406 doi: 10.1016/j.jceh.2024.102406
|
11 |
Gianni TESTINO, Rinaldo PELLICANO. Corrected and republished from: Metabolic associated liver disease. Panminerva Medica 2023; 65(3) doi: 10.23736/S0031-0808.23.04850-4
|
12 |
Cristiane Valle TOVO, Carolina Rossatto RIBAS, Giovana Dal Pozzo SARTORI, Gabriela Perdomo CORAL, Eiji SUWA, Angelo Alves de MATTOS. SPONTANEOUS REGRESSION OF HEPATOCELLULAR CARCINOMA: FOCUSING IN THE ASSOCIATED RISK FACTORS. Arquivos de Gastroenterologia 2024; 61 doi: 10.1590/s0004-2803.24612023-151
|